Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Streptavidin（SA） Hot |Claudin 18.2 |Cadherin-17 
0
There is no goods in the shopping cart !
My Cart|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TIGIT

TIGIT

Brief Information

Name:T cell immunoglobulin and ITIM domains
Target Synonym:V-Set And Immunoglobulin Domain Containing 9,Washington University Cell Adhesion Molecule,V-Set And Transmembrane Domain Containing 3,WUCAM,DKFZp667A205,FLJ39873,V-set and immunoglobulin domain-containing protein 9,TIGIT,VSIG9,T Cell Immunoreceptor With Ig And ITIM Domains,V-Set And Transmembrane Domain-Containing Protein 3,VSIG9, VSTM3,VSTM3,T-Cell Immunoreceptor With Ig And ITIM Domains
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:39
Lastest Research Phase:Phase 3 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BFS-21001 Advanced solid tumors, especially those with high expression of CD155 Complete preliminary pharmacodynamic validation Project authorization, transfer or co-development.
BBS21003 NSCLC, SCLC, multiple myeloma, liver cancer, triple negative breast cancer, pancreatic cancer, etc. Cell line was confirmed, and cell line stability study was completed. The pilot production and toxicology study is being started. Project authorization, transfer or co-development.

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TIT-M82E9 Mouse Biotinylated Mouse TIGIT Protein, His,Avitag™, active dimer (MALS verified)
TIT-M82E9-sds
SCJUR-STF066 Human Human TIGIT (Luc) Jurkat Reporter Cell Development Service
EP-131 Human TIGIT : CD155 [Biotinylated] Inhibitor Screening ELISA Kit
TIT-H52H5 Human Human TIGIT Protein, His Tag, active dimer (MALS verified)
TIT-H52H5-sds
TIT-H82E6 Human Biotinylated Human TIGIT Protein, His,Avitag™, active dimer (recommended for biopanning) (MALS verified)
TIT-H82E6-sds
TIT-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-C5253-structure
TIT-C5253-sds
TIT-M5253 Mouse Mouse TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-M5253-structure
TIT-M5253-sds
TIT-H82F3 Human Biotinylated Human TIGIT Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
TIT-H82F3-structure
TIT-H82F3-sds
TIT-C52H7 Canine Canine TIGIT Protein, His Tag (MALS verified)
TIT-C52H7-structure
TIT-C52H7-sds
TIT-H5253 Human Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
TIT-H5253-structure
TIT-H5253-sds
TIT-R5259 Rabbit Rabbit TIGIT Protein, Fc Tag
TIT-R5259-structure
TIT-R5259-sds
TIT-R5258 Rat Rat TIGIT Protein, Fc Tag
TIT-R5258-structure
TIT-R5258-sds
TIT-C5254 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Fc Tag
TIT-C5254-structure
TIT-C5254-sds
TIT-C5223 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, His Tag (HPLC verified)
TIT-C5223-structure
TIT-C5223-sds
TIT-C5223-hplc
TIT-H82F1 Human Biotinylated Human TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-H82F1-structure
TIT-H82F1-sds
TIT-M52E6 Mouse Mouse TIGIT Protein, His Tag (MALS verified)
TIT-M52E6-structure
TIT-M52E6-sds
TIT-M5257 Mouse Mouse TIGIT Protein, Fc Tag
TIT-M5257-structure
TIT-M5257-sds
TIT-H5254 Human Human TIGIT Protein, Fc Tag (MALS verified)
TIT-H5254-structure
TIT-H5254-sds
ACRO Quality

Part of Bioactivity data

SCJUR-STF066-Cell-based assay
TIGIT FACS

Expression analysis of human TIGIT on Human TIGIT (Luc) Jurkat Reporter Cell by FACS.
Human TIGIT (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human TIGIT antibody.

Protocol
TIT-H5253-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

Protocol
TIT-H52H5-SPR
TIGIT SPR

Anti-hTIGIT antibody captured on CM5 chip via Anti-mouse antibodies surface can bind Human TIGIT, His Tag (Cat. No. TIT-H52H5) with an affinity constant of 1.28 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
TIT-C52H7-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human CD155, Fc Tag (Cat. No. CD5-H5251) on Protein A Biosensor, can bind Canine TIGIT, His Tag (Cat. No. TIT-C52H7) with an affinity constant of 5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Customer Reviews

Synonym Name

TIGIT,VSIG9,VSTM3

Background

TIGIT has been shown to be over expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TIL). Blockade of TIGIT led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells, which now make it be considered as an immune checkpoint. Recently, studies have shown anti-TIGIT antibody is promising to become a cancer immunotherapy. Our ELISA kit is designed to help the discovery of anti-TIGIT therapeutic antibody.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
JS-006 JS-006; TAB-006; CHS-006 Phase 1 Clinical Solid tumours; Neoplasms Details
Belrestotug EOS-448; EOS-884448; GSK-4428859; GSK-4428859A Phase 2 Clinical Iteos Head and Neck Neoplasms; Neoplasms; Multiple Myeloma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
PM-1022 PM-1022 Phase 1 Clinical Biotheus Inc Neoplasms Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
HLX-53 HLX-53 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Lymphoma Details
SEA-TGT SGN-TGT; SEA-TGT; SGN-TIGIT Phase 1 Clinical Seattle Genetics Inc Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Skin Melanoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HL-301 HL-301 Phase 2 Clinical Hanlim Pharm Co Ltd Radiation Pneumonitis; Lung Neoplasms Details
SHS-006(Nanjing Sanhome Pharmaceutical) SHS-006; SH-006; SH006 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours Details
ASP-8374 ASP-8374; PTZ-201 Phase 1 Clinical Potenza Therapeutics, Astellas Pharma Inc Solid tumours; Neoplasms; Glioblastoma Details
Domvanalimab AB-154 Phase 3 Clinical Arcus Biosciences Inc, Gilead Sciences Inc Solid tumours; Glioblastoma; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms Details
DW-2008 DW-2008; DW-2008S Phase 1 Clinical Dong Wha Pharm Co Ltd Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic; Asthma Details
BAT-6021 BAT6021; BAT-6021 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
ZG-005 ZG-005 Phase 2 Clinical Solid tumours Details
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma) LP-010 Phase 1 Clinical Lepu Biotech Co Ltd Solid tumours Details
HH-101 HH-101 Phase 1 Clinical Huahui Health Ltd Solid tumours Details
Tamgiblimab IBI-939 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms; Lung Neoplasms Details
M-6223 M-6223 Phase 1 Clinical Emd Serono Inc, Merck Serono Solid tumours Details
BAT-6005 BAT-6005 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
HB-0036 HB-0036 Phase 2 Clinical Huabo Biopharm Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Vibostolimab MK-7684 Phase 3 Clinical Merck Sharp & Dohme Corp Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
AK-127 AK-127 Phase 1 Clinical Solid tumours; Neoplasms Details
HB0030 HB-0030 Phase 1 Clinical Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
AZD-2936 AZD-2936 Phase 2 Clinical Astrazeneca Plc Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Merck & Co Inc Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Gallbladder Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms Details
BMS-986207 BMS-986207 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BC008-1A BC008-1A Phase 1 Clinical Sichuan Luzhou Buchang Biopharmaceutical Co Ltd Solid tumours Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details
PM-1021 PM1021 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
AUR-106 AUR-106 Phase 1 Clinical Aurigene Discovery Technologies Ltd Neoplasms Details
AGEN-1777 AGEN-1777; BMS-986442 Phase 2 Clinical Agenus Inc Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
AB-308 AB-308 Phase 1 Clinical Arcus Biosciences Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
COM-902 COM-902 Phase 1 Clinical Compugen Ltd Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Colorectal Neoplasms; Lung Neoplasms Details
Etigilimab OMP-313M32 Phase 2 Clinical Oncomed Pharmaceuticals Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
AK-130 AK-130 Phase 1 Clinical Neoplasms Details
Tiragolumab RG-6058; MTIG-7192A; RO-7092284 Phase 3 Clinical F. Hoffmann-La Roche Ltd Carcinoma, Transitional Cell; Hemangioendothelioma, Epithelioid; Adenocarcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Mouth Neoplasms; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Sarcoma; Lymphoma, Follicular; Carcinoma, Medullary; Chordoma; Multiple Myeloma; Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma; Carcinoma, Renal Cell; Rhabdoid Tumor; Rectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Teratoma; Lymphoma, B-Cell; Liver Neoplasms Details
Ociperlimab BGB-A1217 Phase 3 Clinical Beigene Ltd Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap